AssesSment of Early-deteCtion basEd oN liquiD Biopsy in PANCEATIC Cancer (ASCEND-PANCREATIC)
- Conditions
- Cancer
- Registration Number
- NCT05556603
- Lead Sponsor
- Ruijin Hospital
- Brief Summary
ASCEND-PANCREATIC is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, circulating tumor DNA (ctDNA) mutation, serum protein markers and blood miRNA markers, in which of 7,062 participants will be enrolled. The development and validation of the model will be conducted in participants with early stage cancers or benign diseases, along with healthy individuals. The performance of the pancreatic cancer detection test will be evaluated in participants with high risk of pancreatic cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 7062
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The performance of the cfDNA methylation-based model in pancreatic cancer early detection in participants at high risk for pancreatic cancer. 90 months Sensitivity and specificity of the cfDNA methylation-based model in detecting pancreatic cancer. 30 months
- Secondary Outcome Measures
Name Time Method The difference of sensitivity and specificity in pancreatic cancer participants at different clinical stages. 30 months Sensitivity and specificity for detecting pancreatic cancer of a cfDNA methylation-based model, in combination with other biomarkers. 30 months Sensitivity and specificity of a ctDNA mutation-based model and a serum protein-based model in detecting pancreatic cancer, respectively. 30 months
Trial Locations
- Locations (3)
Zhongshan Hospital, Fudan University
🇨🇳Shanghai, Shanghai, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, Shanghai, China
Huashan Hospital, Fudan University
🇨🇳Shanghai, Shanghai, China